In this case, based on tumor heterogeneity, trastuzumab or other HER2-targeting drugs preferentially eradicate HER2+ clonal populations selecting the HER2-negative ones, that in turn emerge and drive tumor progression (41, 42, 44). Here, ERBB2 is linked to neoplasm.